Development of a novel compound series to treat life-threatening, drug-resistant, Staphylococcal infections through the inhibition of the essential cell division protein, FtsZ. (360G-Wellcome-081629_Z_06_G)

£464,800

Drug-resistant Staphylococcal strains represent a growing threat to human health. The emergence of MRSA in particular has received considerable media attention and is attributed to > 1 ,400 of the deaths caused by infections and complicates the treatment of > 7000 patients in UK hospitals per year. With the aid of Trust funding, Prolysis will progress one of their novel antibacterial chemical series that specifically inhibits Staphylococcal cell division through a chemical optimisation programme, preclinical development and into Phase I clinical trials. The project aims to deliver a new targeted therapy for the treatment of Staphylococcal infections acquired in hospitals or the community and to offer a prophylactic treatment for MRSA carriers prior to invasive procedures.

Where is this data from?

This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.

Grant Details

Amount Awarded 464800
Applicant Surname Czaplewski
Approval Committee Seeding Drug Discovery Committee
Award Date 2010-09-21T00:00:00+00:00
Financial Year 2009/10
Grant Programme: Title Seeding Drug Discovery Award
Internal ID 081629/Z/06/G
Lead Applicant Dr Lloyd Czaplewski
Partnership Value 464800
Planned Dates: End Date 2010-12-01T00:00:00+00:00
Planned Dates: Start Date 2007-01-02T00:00:00+00:00
Recipient Org: Country United Kingdom
Region South East